L'intérêt à découvert pour Aardvark Therapeutics donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Aardvark Therapeutics. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Aardvark Therapeutics (NASDAQ:AARD) Stock, Rapport sur les intérêts à découvert

AARDVARK THERAPEUTICS INC

Aardvark Therapeutics

Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.

WIIM

DFDV

DeFi Development shares are trading lower after the company announced plans for a $100 million convertible notes offering.

Cue Biopharma shares are trading higher after the company provided updates and highlighted data for CUE-101.

<p>Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) has outperformed the market over the past 5 years by 8.38% on an annualized basis producing an average annual return of 22.65%. Currently, Spotify Technology has a market capitalization of $148.12 billion. </p>
<p><strong>Buying $100 In SPOT:</strong> If an investor had bought $100 of SPOT stock 5 years ago, it would be worth <strong>$277.55</strong> today based on a price of $722.35 for SPOT at the time of writing.</p>
<h3>Spotify Technology's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751400921_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


News

Trading Ideas

SPOT

$100 Invested In Spotify Technology 5 Years Ago Would Be Worth This Much Today

Wabtec Finalizes Acquisition of Evident's Inspection Technologies Division For $1.78B

General

ALTS

ALT5 Sigma Added As A Member Of The Russell Microcap Growth, Russell 3000E And Russell 3000E Growth Indexes

<p><strong>DeFi Development Corp. (NASDAQ:</strong><a href="https://www.benzinga.com/stock/DFDV#NASDAQ"><strong>DFDV</strong></a><strong>)</strong> (the "Company"), the first US public company with a treasury strategy built to accumulate and compound Solana ("SOL"), today announced that it intends to offer, subject to market conditions and other factors, $100 million aggregate principal amount of convertible senior notes due 2030 (the "Convertible Notes") in a private offering to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The Company also expects to grant the initial purchasers of the Convertible Notes an option to purchase, for settlement within a 13-day period beginning on, and including the date on which the Convertible Notes are first issued, up to an additional $25 million aggregate principal amount of the Convertible Notes.</p>
<p>The Company intends to use a portion of the net proceeds from the offering to repurchase shares of the Company's common stock, par value $0.00001 per share (the "common stock") through the prepaid forward described below.&nbsp; The Company expects to use the remainder of the net proceeds from the offering for general corporate purposes, including the acquisition of SOL.</p>


Offerings

DeFi Development Corp. Plans $100M Convertible Notes Offering To Fund Stock Buyback And Solana Acquisitions

<p>Jefferies  analyst Edison Lee   upgrades Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) from Underperform to Hold and raises the price target from $170.62 to $188.32.</p>


Upgrades

Price Target

Analyst Ratings

AAPL

Jefferies Upgrades Apple to Hold, Raises Price Target to $188.32

<p>Constellation Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) affirms FY2026 Adj EPS guidance from $12.60-$12.90 to $12.60-$12.90 vs $12.69 analyst estimate..</p>


Guidance

Constellation Brands Affirms FY2026 Adj EPS Guidance of $12.60-$12.90 vs $12.69 Est

<p><i>ORR of 50% in treatment-naïve patients with HPV+ R/M HNSCC</i><br /><br /><i>12-month landmark survival of 88% and mOS of 32 months</i></p>
<p>BOSTON, July 01, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=U6uZoiaYsN9XtZjW8KdVnHlrgRQAThJuaNXzmvQfRDT7p03ofum_3l56cvLb6Oo_K9BWGavjLtHwb3OdGUmh15kntbjvB2LfH98FVwP0XXRrotMkSJS3ZEeoga9tx-C66vQ7XfXQkufw1IfSY2s0ag97kHuBdgbRor2B1lwj3tJ2nCxTJhkKP6JfGOIo7BwwSw1W6qmMDVuMT7ETXAVIN29EUmGQRkT3sAH0UzSxu83wBMDW3KvhE_oeVXx8HIHmhm-CYhN2hMgRcc599LCSPg==">Cue Biopharma, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, today provided an update on its most advanced clinical stage asset, CUE-101, representative of the CUE-100 series.</p>
<p>Dr. Dimitrios Colevas presented new data from the company's maturing Phase 1 trial evaluating CUE-101 in combination with KEYTRUDA&#xAE; (pembrolizumab) for patients with recurrent metastatic HPV+ head and neck squamous cell carcinoma (HNSCC). Data highlights include an overall response rate (ORR) of 50% (with 1 unconfirmed PR) in patients with combined positive score (CPS) &gt;1 and an ORR of 50% observed in patients with low CPS scores (1-19). This compares favorably to the historical ORR of 19% observed with pembrolizumab alone in the third-party KEYNOTE 048 trial. Notably, the 12-month overall survival (OS) of 88% in the Phase 1 trial represents a significant reduction in the risk of death (HR 0.23) compared to historical data from the KEYNOTE 048 study. The Kaplan-Meier (K-M) estimate for median overall survival (mOS) is currently 32 months.</p>


Cue Biopharma Issues Update On Its Clinical Stage Asset, CUE-101, Representative Of CUE-100 Series; Data Highlights Include ORR Of 50% In Treatment-Naive Patients With HPV+ R/M HNSCC

<p><a href="https://www.globenewswire.com/Tracker?data=Kwadq9hGybbR4rqgXHlCISdNA55RyVG0qFRoVl_IBiaRnnVDNG7A4aVakfQujHaoDE94q3YtHKHigI1AZlgg_vsFv7dSh5RORHYo4bYSOtBmEhHNkgcxHdcZGWkz82RX">Eos Energy Enterprises, Inc. (NASDAQ:</a><a href="https://www.benzinga.com/stock/EOSE#NASDAQ">EOSE</a>) ("Eos" or the "Company"), an American energy company and the leading innovator in designing, sourcing, manufacturing, and providing zinc-based battery energy storage systems (BESS) manufactured in the United States, today announced that it has received its second loan advance from the Department of Energy's (DOE) Loan Programs Office in the amount of $22.7 million. With this advance, the Company has fully drawn the maximum allowable amount under the first tranche of $90.9 million in connection with the completion of its first state-of-the-art manufacturing line.</p>
<p>The loan advance covers 80% of eligible costs, incurred as part of the Company's production expansion plans related to Project AMAZE. These funds support Eos' ongoing efforts to expand its operational capacity to meet growing customer demand and further its strategic growth objectives.</p>


Financing

EOSE

Eos Energy Draws Full $90.9M DOE Loan Tranche To Boost U.S. Zinc Battery Production

<p>Constellation Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) reported quarterly earnings of $3.22 per share which missed the analyst consensus estimate of $3.31 by 2.6 percent. This is a 9.8 percent decrease over earnings of $3.57 per share from the same period last year.  The company reported quarterly sales of $2.515 billion which missed the analyst consensus estimate of $2.554 billion by 1.52 percent.  This is a 5.52 percent decrease over sales of $2.662 billion the same period last year.</p>


Earnings

Earnings Misses

Constellation Brands Q1 Adj. EPS $3.22 Misses $3.31 Estimate, Sales $2.515B Miss $2.554B Estimate

VERO

Venus Concept Announces Exchanges $6.5M Of Subordinated Convertible Notes Held By Affiliates Of Madryn Asset Management, LP For 325,651 Shares Of Series Y Preferred Stock

<p>ArriVent BioPharma, Inc. ("ArriVent") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVBP#NASDAQ">AVBP</a>), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that it intends to offer and sell, subject to market and other conditions, $75 million of its shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock, in an underwritten public offering. In addition, ArriVent expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the total amount of common stock and shares of common stock underlying pre-funded warrants on the same terms and conditions. All of the securities are being offered by ArriVent.</p>
<p>Goldman Sachs &amp; Co. LLC, Citigroup and Guggenheim Securities are acting as joint book-running managers for the proposed offering.</p>


AVBP

ArriVent Announces Proposed $75M Public Offering Of Common Stock

Management

ORKA

Oruka Therapeutics Promotes Laura Sandler To Chief Operating Officer

<p>Bank OZK (the &quot;Bank&quot;) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OZK#NASDAQ">OZK</a>) announced its Board of Directors declared a quarterly cash dividend on the Bank&#39;s common stock of $0.44 per share, up $0.01, or 2.33% from the prior quarter. The common stock dividend is payable on July 18, 2025 to shareholders of record as of July 11, 2025. Bank OZK has increased its quarterly cash dividend on its common stock in each of the last sixty quarters.</p>


Dividends

Bank OZK Announces Increase To Quarterly Common Stock Dividend From $0.43 To $0.44 Per Share

<p>Financial giants have made a conspicuous bullish move on Chevron. Our analysis of options history for Chevron (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) revealed 10 unusual trades.</p>
<p>Delving into the details, we found 50% of traders were bullish, while 40% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $1,268,015, and 5 were calls, valued at $217,310.</p>
<h3>Expected Price Movements</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $115.0 to $165.0 for Chevron over the recent three months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Chevron's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Chevron's whale trades within a strike price range from $115.0 to $165.0 in the last 30 days. </p>
<h3>Chevron Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751400116_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CVX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$7.3</td>
<td>$7.2</td>
<td>$7.29</td>
<td>$140.00</td>
<td>$1.0M</td>
<td>1.8K</td>
<td>1.5K</td>
</tr>
<tr>
<td>CVX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$5.75</td>
<td>$5.65</td>
<td>$5.75</td>
<td>$145.00</td>
<td>$57.5K</td>
<td>4.3K</td>
<td>114</td>
</tr>
<tr>
<td>CVX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$29.15</td>
<td>$28.0</td>
<td>$29.15</td>
<td>$165.00</td>
<td>$55.4K</td>
<td>52</td>
<td>19</td>
</tr>
<tr>
<td>CVX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$3.45</td>
<td>$3.35</td>
<td>$3.45</td>
<td>$165.00</td>
<td>$51.7K</td>
<td>3.8K</td>
<td>210</td>
</tr>
<tr>
<td>CVX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$10.65</td>
<td>$10.35</td>
<td>$10.35</td>
<td>$130.00</td>
<td>$45.5K</td>
<td>1.0K</td>
<td>94</td>
</tr>
</tbody>
</table>
</p>
<h3>About Chevron</h3>
<p>Chevron is an integrated energy company with exploration, production, and refining operations worldwide. It is the second-largest oil company in the United States with production of 3.0 million of barrels of oil equivalent a day, including 7.7 million cubic feet a day of natural gas and 1.7 million of barrels of liquids a day. Production activities take place in North America, South America, Europe, Africa, Asia, and Australia. Its refineries are in the US and Asia for total refining capacity of 1.8 million barrels of oil a day. Proven reserves at year-end 2024 stood at 9.8 billion barrels of oil equivalent, including 5.1 billion barrels of liquids and 28.4 trillion cubic feet of natural gas.</p>
<p>In light of the recent options history for Chevron, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Current Position of Chevron</h3>
<ul>
<li>Currently trading with a volume of 6,031,437, the CVX's price is up by 1.98%, now at $146.03. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 31 days.</li>
</ul>
<h3>What The Experts Say On Chevron</h3>
<p>1 market experts have recently issued ratings for this stock, with a consensus target price of $165.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on Chevron with a target price of $165. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Chevron options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


Options

Markets

Spotlight on Chevron: Analyzing the Surge in Options Activity

<p>Deep-pocketed investors have adopted a bullish approach towards Archer Aviation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in ACHR usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 25 extraordinary options activities for Archer Aviation. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 40% leaning bullish and 40% bearish. Among these notable options, 2 are puts, totaling $397,000, and 23 are calls, amounting to $1,484,599.</p>
<h3>Predicted Price Range</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $3.5 to $17.0 for Archer Aviation over the last 3 months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Archer Aviation's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Archer Aviation's significant trades, within a strike price range of $3.5 to $17.0, over the past month.</p>
<h3>Archer Aviation Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751400111_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ACHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/08/25</td>
<td>$0.79</td>
<td>$0.78</td>
<td>$0.79</td>
<td>$10.00</td>
<td>$316.0K</td>
<td>5.0K</td>
<td>4.0K</td>
</tr>
<tr>
<td>ACHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$7.1</td>
<td>$7.0</td>
<td>$7.0</td>
<td>$4.00</td>
<td>$175.1K</td>
<td>4.0K</td>
<td>256</td>
</tr>
<tr>
<td>ACHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$2.33</td>
<td>$2.29</td>
<td>$2.33</td>
<td>$8.00</td>
<td>$116.5K</td>
<td>460</td>
<td>2.5K</td>
</tr>
<tr>
<td>ACHR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$2.33</td>
<td>$2.28</td>
<td>$2.32</td>
<td>$8.00</td>
<td>$116.0K</td>
<td>460</td>
<td>2.0K</td>
</tr>
<tr>
<td>ACHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$2.33</td>
<td>$2.28</td>
<td>$2.32</td>
<td>$8.00</td>
<td>$116.0K</td>
<td>460</td>
<td>2.0K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Archer Aviation</h3>
<p>Archer Aviation Inc advances the benefits of sustainable air mobility. The company is engaged in designing and developing a fully electric vertical takeoff and landing eVTOL aircraft for use in UAM networks. It is creating an electric airline that moves people throughout cities in a quick, safe, sustainable, and cost-effective manner.</p>
<h3>Current Position of Archer Aviation</h3>
<ul>
<li>Trading volume stands at 48,846,482, with ACHR's price down by -8.62%, positioned at $9.91.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 37 days.</li>
</ul>
<h3>What The Experts Say On Archer Aviation</h3>
<p>Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $14.67.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Canaccord Genuity continues to hold a Buy rating for Archer Aviation, targeting a price of $13.<br />
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $13.<br />
&#x2A; Consistent in their evaluation, an analyst from HC Wainwright &amp; Co. keeps a Buy rating on Archer Aviation with a target price of $18. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Archer Aviation options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


ACHR

Spotlight on Archer Aviation: Analyzing the Surge in Options Activity

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Seagate Tech Hldgs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with STX, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 32 uncommon options trades for Seagate Tech Hldgs.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 40% bullish and 46%, bearish.</p>
<p>Out of all of the special options we uncovered, 19 are puts, for a total amount of $1,163,980, and 13 are calls, for a total amount of $664,810.</p>
<h3>What's The Price Target?</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $105.0 and $165.0 for Seagate Tech Hldgs, spanning the last three months.</p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Seagate Tech Hldgs's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Seagate Tech Hldgs's whale activity within a strike price range from $105.0 to $165.0 in the last 30 days. </p>
<h3>Seagate Tech Hldgs Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751400105_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>STX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$35.3</td>
<td>$35.0</td>
<td>$35.0</td>
<td>$165.00</td>
<td>$175.0K</td>
<td align="right">0</td>
<td align="right">157</td>
</tr>
<tr>
<td>STX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$3.8</td>
<td>$3.5</td>
<td>$3.7</td>
<td>$145.00</td>
<td>$137.6K</td>
<td align="right">363</td>
<td align="right">505</td>
</tr>
<tr>
<td>STX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$35.3</td>
<td>$35.0</td>
<td>$35.0</td>
<td>$165.00</td>
<td>$136.5K</td>
<td align="right">0</td>
<td align="right">107</td>
</tr>
<tr>
<td>STX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/17/27</td>
<td>$38.0</td>
<td>$37.3</td>
<td>$37.4</td>
<td>$165.00</td>
<td>$127.1K</td>
<td align="right">58</td>
<td align="right">136</td>
</tr>
<tr>
<td>STX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/17/27</td>
<td>$35.1</td>
<td>$34.6</td>
<td>$34.6</td>
<td>$160.00</td>
<td>$89.9K</td>
<td align="right">20</td>
<td align="right">50</td>
</tr>
</tbody>
</table>
</p>
<h3>About Seagate Tech Hldgs</h3>
<p>Seagate is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital; they are both vertically integrated.</p>
<p>Following our analysis of the options activities associated with Seagate Tech Hldgs, we pivot to a closer look at the company's own performance.</p>
<h3>Present Market Standing of Seagate Tech Hldgs</h3>
<ul>
<li>With a volume of 3,960,244, the price of STX is down -0.39% at $143.76. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 21 days.</li>
</ul>
<h3>What Analysts Are Saying About Seagate Tech Hldgs</h3>
<p>1 market experts have recently issued ratings for this stock, with a consensus target price of $145.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from B of A Securities keeps a Buy rating on Seagate Tech Hldgs with a target price of $145. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Seagate Tech Hldgs, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Seagate Tech Hldgs Unusual Options Activity For July 01

<p>Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) has outperformed the market over the past 20 years by 13.87% on an annualized basis producing an average annual return of 22.35%. Currently, Regeneron Pharmaceuticals has a market capitalization of $56.34 billion. </p>
<p><strong>Buying $100 In REGN:</strong> If an investor had bought $100 of REGN stock 20 years ago, it would be worth <strong>$5,977.36</strong> today based on a price of $521.83 for REGN at the time of writing.</p>
<h3>Regeneron Pharmaceuticals's Performance Over Last 20 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751400083_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


REGN

Here's How Much $100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today

<p><strong>Citigroup's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) short percent of float has risen 3.59% since its last report. The company recently reported that it has <strong>32.21 million shares sold short</strong>, which is 1.73% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 3.12 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>Citigroup Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751400030_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Citigroup has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Citigroup's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Citigroup's peer group average for short interest as a percentage of float is 0.90%, which means the company has <strong>more</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Comments

Aardvark Therapeutics

Intérêt court

Aardvark Therapeutics (NASDAQ:AARD) Stock, Rapport sur les intérêts à découvert

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL